Delix Therapeutics raises $70m

The round in the neuroscience company was led by ARTIS Ventures, RA Capital Management and founding investor OMX Ventures.

Boston-based Delix Therapeutics, a neuroscience company focused on treating mental health disorders, has raised $70 million in Series A financing. The round was led by ARTIS Ventures, RA Capital Management and founding investor OMX Ventures.

Additional investors participating in the round include: Apeiron, Bail Capital, Casa Verde Capital, Dolby Family Ventures, Negev Capital, Noetic Fund, Ocama Partners, Palo Santo, Presight Capital, PsyMed Ventures, R2, Re.Mind Capital, Saya Bio, Vertical Venture Partners, WPSS and other family investment funds.

Source: Company press release